NBIX Insider Transactions — Page 9
1,692 retained open-market purchase and sale rows from SEC Forms 3, 4 and 5, newest first. This page shows rows 801–900; provenance stays internal.
| Insider profile | Role | Date | Transaction | Shares | Price |
|---|---|---|---|---|---|
| OBrien Christopher Flint | Chief Medical Officer | 2014-12-10 | Sale | 20,000.0 | $21.55 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-12-10 | Sale | 125.0 | $22.0 |
| Coughlin Timothy P | Chief Financial Officer | 2014-12-10 | Sale | 10,000.0 | $21.95 |
| Coughlin Timothy P | Chief Financial Officer | 2014-12-10 | Sale | 10,000.0 | $21.0 |
| Coughlin Timothy P | Chief Financial Officer | 2014-11-28 | Sale | 10,000.0 | $20.14 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-11-24 | Sale | 5,463.0 | $19.53 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-11-17 | Sale | 11,300.0 | $19.51 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-11-13 | Sale | 3,237.0 | $19.5 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-11-10 | Sale | 20,000.0 | $18.62 |
| Coughlin Timothy P | Chief Financial Officer | 2014-10-31 | Sale | 10,000.0 | $19.0 |
| Coughlin Timothy P | Chief Financial Officer | 2014-10-30 | Sale | 10,000.0 | $18.62 |
| Coughlin Timothy P | Chief Financial Officer | 2014-10-28 | Sale | 10,000.0 | $18.0 |
| MITCHELL W THOMAS | Director | 2014-10-01 | Sale | 1,275.0 | $15.5 |
| LYONS GARY A | Director | 2014-09-15 | Sale | 20,000.0 | $15.66 |
| Bozigian Haig P. | CHIEF DEVELOPMENT OFFICER | 2014-01-17 | Sale | 25,000.0 | $20.0 |
| Grigoriadis Dimitri E. | CHIEF RESEARCH OFFICER | 2014-01-17 | Sale | 25,000.0 | $20.0 |
| GORMAN KEVIN CHARLES | President and CEO | 2014-01-10 | Sale | 3,750.0 | $18.57 |
| Coughlin Timothy P | Chief Financial Officer | 2014-01-10 | Sale | 1,750.0 | $18.56 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-01-10 | Sale | 1,750.0 | $18.55 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-01-10 | Sale | 5,000.0 | $19.0 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2014-01-10 | Sale | 1,625.0 | $18.56 |
| Bozigian Haig P. | Chief Development Officer | 2014-01-10 | Sale | 1,625.0 | $18.58 |
| Gano Kyle | Chief Business Dev Officer | 2014-01-10 | Sale | 1,250.0 | $18.57 |
| GORMAN KEVIN CHARLES | President and CEO | 2014-01-07 | Sale | 108,000.0 | $16.76 |
| Coughlin Timothy P | Chief Financial Officer | 2014-01-07 | Sale | 70,000.0 | $16.75 |
| OBrien Christopher Flint | Chief Medical Officer | 2014-01-07 | Sale | 5,000.0 | $17.5 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2014-01-07 | Sale | 25,000.0 | $17.5 |
| Bozigian Haig P. | Chief Development Officer | 2014-01-07 | Sale | 25,000.0 | $17.5 |
| Gano Kyle | Chief Business Dev Officer | 2013-09-04 | Sale | 2,400.0 | $15.61 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-09-03 | Sale | 5,000.0 | $16.0 |
| Coughlin Timothy P | Chief Financial Officer | 2013-08-21 | Sale | 19,035.0 | $15.05 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-08-21 | Sale | 6,475.0 | $15.01 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-08-21 | Sale | 7,125.0 | $15.08 |
| Bozigian Haig P. | Chief Development Officer | 2013-08-21 | Sale | 6,874.0 | $15.01 |
| Bozigian Haig P. | Chief Development Officer | 2013-08-21 | Sale | 7,125.0 | $15.07 |
| MITCHELL W THOMAS | Director | 2013-08-06 | Sale | 1,531.0 | $14.7 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-08-05 | Sale | 5,000.0 | $15.0 |
| Coughlin Timothy P | Chief Financial Officer | 2013-08-05 | Sale | 10,965.0 | $14.99 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-08-05 | Sale | 6,400.0 | $15.01 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-08-05 | Sale | 5,000.0 | $15.0 |
| Bozigian Haig P. | Chief Development Officer | 2013-08-05 | Sale | 6,001.0 | $15.0 |
| Bozigian Haig P. | Chief Development Officer | 2013-08-05 | Sale | 5,000.0 | $15.0 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-07-12 | Sale | 5,000.0 | $14.5 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-28 | Sale | 7,500.0 | $13.5 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-27 | Sale | 3,857.0 | $13.0 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-06-27 | Sale | 3,837.0 | $13.0 |
| Bozigian Haig P. | Chief Development Officer | 2013-06-27 | Sale | 8,000.0 | $13.0 |
| Bozigian Haig P. | Chief Development Officer | 2013-06-24 | Sale | 769.0 | $12.72 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-21 | Sale | 8,783.0 | $12.58 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-21 | Sale | 1,143.0 | $13.01 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-21 | Sale | 5,000.0 | $12.5 |
| Bozigian Haig P. | Chief Development Officer | 2013-06-21 | Sale | 500.0 | $13.0 |
| Bozigian Haig P. | Chief Development Officer | 2013-06-21 | Sale | 3,462.0 | $12.5 |
| Bozigian Haig P. | Chief Development Officer | 2013-06-21 | Sale | 20,000.0 | $12.68 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-06-21 | Sale | 937.0 | $13.0 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-06-21 | Sale | 900.0 | $13.0 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-06-21 | Sale | 4,100.0 | $12.5 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-06-21 | Sale | 20,000.0 | $12.69 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-20 | Sale | 1,217.0 | $12.56 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-20 | Sale | 10,000.0 | $12.2 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-20 | Sale | 5,000.0 | $12.37 |
| OBrien Christopher Flint | Chief Medical Officer | 2013-06-20 | Sale | 5,000.0 | $12.45 |
| Bozigian Haig P. | Chief Development Officer | 2013-06-20 | Sale | 769.0 | $12.55 |
| Bozigian Haig P. | Chief Development Officer | 2013-06-20 | Sale | 20,000.0 | $12.3 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-06-20 | Sale | 20,000.0 | $12.29 |
| Grigoriadis Dimitri E. | Chief Research Officer | 2013-06-20 | Sale | 900.0 | $12.54 |
| MITCHELL W THOMAS | Director | 2012-12-05 | Sale | 900.0 | $7.41 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 2011-10-12 | Purchase | 22,300.0 | $5.96 |
| BVF PARTNERS L P/IL | TenPercentOwner | 2011-10-12 | Purchase | 22,300.0 | $5.96 |
| BVF INC/IL | TenPercentOwner | 2011-10-12 | Purchase | 22,300.0 | $5.96 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 2011-10-12 | Purchase | 22,300.0 | $5.96 |
| BVF INVESTMENTS LLC | Other | 2011-10-12 | Purchase | 22,300.0 | $5.96 |
| LAMPERT MARK N | TenPercentOwner | 2011-10-12 | Purchase | 22,300.0 | $5.96 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 2011-10-12 | Purchase | 1,000.0 | $5.96 |
| BVF PARTNERS L P/IL | TenPercentOwner | 2011-10-12 | Purchase | 1,000.0 | $5.96 |
| BVF INC/IL | TenPercentOwner | 2011-10-12 | Purchase | 1,000.0 | $5.96 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 2011-10-12 | Purchase | 1,000.0 | $5.96 |
| BVF INVESTMENTS LLC | Other | 2011-10-12 | Purchase | 1,000.0 | $5.96 |
| LAMPERT MARK N | TenPercentOwner | 2011-10-12 | Purchase | 1,000.0 | $5.96 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 2011-10-12 | Purchase | 6,200.0 | $5.96 |
| BVF PARTNERS L P/IL | TenPercentOwner | 2011-10-12 | Purchase | 6,200.0 | $5.96 |
| BVF INC/IL | TenPercentOwner | 2011-10-12 | Purchase | 6,200.0 | $5.96 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 2011-10-12 | Purchase | 6,200.0 | $5.96 |
| BVF INVESTMENTS LLC | Other | 2011-10-12 | Purchase | 6,200.0 | $5.96 |
| LAMPERT MARK N | TenPercentOwner | 2011-10-12 | Purchase | 6,200.0 | $5.96 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 2011-10-11 | Purchase | 3,800.0 | $5.73 |
| BVF PARTNERS L P/IL | TenPercentOwner | 2011-10-11 | Purchase | 3,800.0 | $5.73 |
| BVF INC/IL | TenPercentOwner | 2011-10-11 | Purchase | 3,800.0 | $5.73 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 2011-10-11 | Purchase | 3,800.0 | $5.73 |
| BVF INVESTMENTS LLC | Other | 2011-10-11 | Purchase | 3,800.0 | $5.73 |
| LAMPERT MARK N | TenPercentOwner | 2011-10-11 | Purchase | 3,800.0 | $5.73 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 2011-10-10 | Purchase | 44,700.0 | $5.59 |
| BVF PARTNERS L P/IL | TenPercentOwner | 2011-10-10 | Purchase | 44,700.0 | $5.59 |
| BVF INC/IL | TenPercentOwner | 2011-10-10 | Purchase | 44,700.0 | $5.59 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 2011-10-10 | Purchase | 44,700.0 | $5.59 |
| BVF INVESTMENTS LLC | Other | 2011-10-10 | Purchase | 44,700.0 | $5.59 |
| LAMPERT MARK N | TenPercentOwner | 2011-10-10 | Purchase | 44,700.0 | $5.59 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 2011-10-10 | Purchase | 9,600.0 | $5.59 |
| BVF PARTNERS L P/IL | TenPercentOwner | 2011-10-10 | Purchase | 9,600.0 | $5.59 |
| BVF INC/IL | TenPercentOwner | 2011-10-10 | Purchase | 9,600.0 | $5.59 |